ES2623281T3 - Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. - Google Patents

Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. Download PDF

Info

Publication number
ES2623281T3
ES2623281T3 ES13160120.5T ES13160120T ES2623281T3 ES 2623281 T3 ES2623281 T3 ES 2623281T3 ES 13160120 T ES13160120 T ES 13160120T ES 2623281 T3 ES2623281 T3 ES 2623281T3
Authority
ES
Spain
Prior art keywords
solid pharmaceutical
proton pump
pharmaceutical compositions
enteric coated
pump inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13160120.5T
Other languages
English (en)
Inventor
Ümit Cifter
Ali TÜRKYILMAZ
Onur Mutlu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Application granted granted Critical
Publication of ES2623281T3 publication Critical patent/ES2623281T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica sólida para administración oral que comprende; i. un núcleo que comprende un inhibidor de la bomba de protones, un antiácido y uno o más excipientes farmacéuticamente aceptables ii. una capa intermedia, y iii. una capa de recubrimiento entérico caracterizada por que, a. la capa intermedia comprende un polímero celulósico, b. la capa de recubrimiento entérico comprende una composición polimérica y, opcionalmente, un plastificante, comprendiendo dicha composición polimérica dos polímeros entéricos que tienen diferentes características de solubilidad que son; - acetato succinato de hidroxipropilmetilcelulosa que tiene una calidad superior, que tiene una solubilidad en función del pH >= 6,8 o >= 6,0 y - acetato succinato de hidroxipropilmetilcelulosa que tiene una calidad inferior, que tiene una solubilidad en función del pH >= 5,5 o >= 6,0.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
    imagen2
ES13160120.5T 2012-03-21 2013-03-20 Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. Active ES2623281T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201203193 2012-03-21
TR201203193 2012-03-21

Publications (1)

Publication Number Publication Date
ES2623281T3 true ES2623281T3 (es) 2017-07-10

Family

ID=47891542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13160120.5T Active ES2623281T3 (es) 2012-03-21 2013-03-20 Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones.

Country Status (4)

Country Link
EP (1) EP2641594B1 (es)
ES (1) ES2623281T3 (es)
PL (1) PL2641594T3 (es)
WO (1) WO2013141827A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586792A (zh) * 2014-12-25 2015-05-06 北京华禧联合科技发展有限公司 一种右兰索拉唑肠溶制剂
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20170056342A1 (en) * 2015-08-31 2017-03-02 Apotex Technologies Inc. Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201701461A2 (tr) * 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
TR201723199A2 (tr) * 2017-12-30 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Yeni farmasötik bileşimler.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ES2392960T3 (es) * 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
EP2384747A3 (en) * 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole

Also Published As

Publication number Publication date
WO2013141827A1 (en) 2013-09-26
EP2641594B1 (en) 2017-02-01
EP2641594A3 (en) 2013-11-06
EP2641594A2 (en) 2013-09-25
PL2641594T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
ES2623281T3 (es) Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones.
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
EA201892836A1 (ru) Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CO6731132A2 (es) Comprimido de desintegración oral
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
CL2012003031A1 (es) Un metodo para administrar un lugar de investigacion de semillas.
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CL2009000330A1 (es) Composicion farmaceutica que comprende microcapsulas de sabor enmascarado con un nucleo de ranitidina y al menos dos recubrimientos sobre el; tabla de rapida desintegracion oral; metodo para preparar la composicion farmaceutica; metodo para preparar la tableta, util para tratar o prevenir trastornos gastrointestinales.
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
CO7350622A2 (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
JP2018118936A5 (es)
EA201490500A1 (ru) Многослойный высвобождающий состав
AR097202A1 (es) Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa
ES2598753T3 (es) Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada
CL2017003350A1 (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc